Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)
Brief Summary: This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis. The primary hypotheses of the study are that tildrakizumab is superior to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of participants achieving \>= Psoriasis Area Sensitivity Index of 75% (PASI-75) response and the proportion of participants with a Physician's Global Assessment (PGA) score of "clear" or "minimal" with at least a 2 grade reduction from baseline at Week 12.


Options:
A: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Etanercept Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Etanercept Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept Placebo | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Tildrakizumab Placebo; Assigned to Arm(s): Etanercept 50 mg, Placebo | Intervention Type: DRUG; Name: Etanercept Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
B: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
C: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: A